HIV Vaccine :: GeoVax comments on Merck’s HIV vaccine trial
Merck & Co., Inc. announced their candidate AIDS vaccine failed to provide protection in a human study designed to test for efficacy. In this Merck trial involving high risk volunteers, an equal number of people received either placebo or AIDS vaccine. The independent Data Safety Monitoring Board recommended that the trial be stopped because it was not reaching its efficacy endpoints.